Skip to main content

Fiscal Wizard · Single-issue tearsheet

TECH / Aug 13, 2026 Run #13805

TECH

Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Composite verdict

F 22.0 / 100
Gated stand-aside 0 drivers · 4 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 5th of 7 in Biotechnology

rescore-sweep
Technical synthesisRegime: uptrend

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -79%
Asset value $12.31Earnings power value $4.26Price $72.23

Priced above its no-growth earnings power value ($4.26/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

22.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Margin of Safety 0
OCF to Net Income 0
Cash Conversion 0

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 44 signals shown.

Risk Gates

4 blocking 5 caution

4 guards active, 44 signals gated.

Earnings Event Blackout Blocking

Mutes all technical signals within the earnings announcement window when earnings dates are available.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for TECH.